Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 3
1981 1
1982 3
1983 5
1984 4
1985 5
1986 5
1987 10
1988 7
1989 8
1990 9
1991 11
1992 11
1993 18
1994 15
1995 16
1996 13
1997 26
1998 18
1999 23
2000 18
2001 29
2002 31
2003 27
2004 36
2005 55
2006 54
2007 83
2008 100
2009 116
2010 136
2011 139
2012 148
2013 144
2014 189
2015 208
2016 244
2017 312
2018 291
2019 329
2020 352
2021 411
2022 516
2023 472
2024 549
2025 570
2026 394

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,512 results

Results by year

Filters applied: . Clear all
Page 1
Targeting β-catenin degradation with GSK3β inhibitors induces cell death in acute lymphoblastic leukemia.
Cosgun KN, Jumaa H, Robinson ME, Cheng Z, Oulghazi S, Kume K, Fonseca Arce D, Agadzhanian N, Kistner KM, Leveille E, Drivet E, Yu F, Qian Z, Song JY, Chan WC, Xu L, Xiao G, Taketo MM, Kothari S, Davids MS, Schjerven H, Jellusova J, Müschen M. Cosgun KN, et al. Among authors: qian z. Nat Cancer. 2026 Jan;7(1):150-168. doi: 10.1038/s43018-025-01093-z. Epub 2026 Jan 8. Nat Cancer. 2026. PMID: 41507538 Free PMC article.
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.
Li H, Liu J, Ouyang Q, Wang S, Liu Y, Teng Y, Wang X, Cheng J, Tong Z, Sun T, Yan M, Zhou X, Li F, Nie J, Shao ZM, Ye C, Wang Y, Wu X, Li Z, Wu Y, Xiong H, Li H, Gan L, Niu Z, Zhang J, Zhang Q, Pan Y, Wu X, Zhang Y, Xie W, Xiao Y, Gao J, Zhao H, Yin Y, Qian Z, Sun S, Zhang H, Wang K, Lu J, Li Y, Wang X, Yang X, Wang Y, Wang Q, Song E. Li H, et al. Among authors: qian z. Lancet Oncol. 2025 Dec;26(12):1563-1574. doi: 10.1016/S1470-2045(25)00523-6. Lancet Oncol. 2025. PMID: 41308673 Clinical Trial.
5,512 results